Destiny Pharma reports progress on clinical assets
4th Jan 2024 11:27
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
Read moreSunday share tips: Destiny Pharma, Invinity Energy Systems
29th Oct 2023 21:01
(Sharecast News) - The Financial Mail on Sunday's Midas column spied long-term potential in Destiny Pharma's shares.
Read moreDestiny Pharma loss widens as it extends cash runway
13th Apr 2023 14:16
(Sharecast News) - Biotechnology company Destiny Pharma reported a loss before tax of £7.7m in its 2022 results on Thursday, widening from £6.3m in the prior year.
Read moreDestiny Pharma upbeat on infection prevention study
4th Apr 2023 11:33
(Sharecast News) - Destiny Pharma said in an update on Tuesday that its novel medicine for preventing life-threatening infections, 'NTCD-M3', had been shown to colonise the gut successfully in a C difficile infection (CDI) model study after the administration of fidaxomicin.
Read moreDestiny publishes 'important' research on its preoperative treatment candidate
24th Mar 2023 15:34
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the publication of landmark clinical data for 'XF-73' on Friday, in the US-based peer-reviewed journal Infection Control & Hospital Epidemiology.
Read moreDestiny Pharma jumps on 2022 progress
22nd Dec 2022 14:06
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to finalise a partnering agreement for 'NTCD-M3', which it described as its "most advanced" clinical programme, targeted at infection prevention.
Read moreDestiny Pharma finalises plans for next study of its lead asset
7th Dec 2022 16:27
(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.
Read moreDestiny Pharma starts new safety study of dermal formulation
15th Nov 2022 12:53
(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.
Read moreDestiny Pharma receives 'positive feedback' from EMA on NTCD-M3
7th Sep 2022 08:06
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.
Read moreDestiny Pharma awarded Cystic Fibrosis Foundation project
12th Jul 2022 15:39
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.
Read moreDestiny Pharma appoints Yuri Martina as chief medical officer
3rd May 2022 12:16
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the appointment of Dr Yuri Martina as its chief medical officer on Tuesday.
Read moreDestiny Pharma to raise up to £7m in discounted fundraising
8th Mar 2022 13:55
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma said on Tuesday that it was looking to raise up to £7m in a conditional fundraising to continue progress towards Phase 3 in its two lead clinical assets.
Read moreDestiny upbeat on nasal gel feedback from EMA
8th Feb 2022 15:07
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Tuesday that it has received positive scientific advice from the European Medicines Agency (EMA), following its review of its proposed phase 3 clinical programme design.
Read moreDestiny successfully completes preclinical study of dermal formulation
1st Feb 2022 14:57
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful completion of a preclinical safety study with a novel 'XF-73' dermal formulation on Tuesday.
Read moreDestiny Pharma reports success in US C. diff trial
24th Jan 2022 13:44
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful outcome of its cooperative research and development agreement with the US Department of Veterans Affairs (VA) on Monday.
Read more